Yupelri is a medication used to treat bronchopulmonary dysplasia (BPD) in preterm infants. It is administered as an inhalation solution [1].
What is Yupelri approved for?
Yupelri is approved for the treatment of bronchopulmonary dysplasia (BPD) in preterm infants [1].
How does Yupelri work?
Yupelri is a liquid formulation of recombinant human insulin-like growth factor-1 (rhIGF-1). It is delivered via inhalation [1].
Who makes Yupelri?
UPEREG is manufactured by Insmed [2].
What is the clinical data supporting Yupelri?
Clinical trials have demonstrated that Yupelri can help improve certain lung function measures in preterm infants with BPD. Specifically, it has shown a reduction in the need for supplemental oxygen and mechanical ventilation [1].
What are the potential side effects of Yupelri?
The most common side effects reported in clinical studies for Yupelri include worsened bronchopulmonary dysplasia, feeding intolerance, and intraventricular hemorrhage [1].
What is the regulatory status of Yupelri?
Yupelri received FDA approval for its indication. The drug has also been granted orphan drug exclusivity [1].
When does Yupelri's patent expire?
Information regarding the specific patent expiration dates for Yupelri is available through specialized patent tracking services. DrugPatentWatch.com provides detailed patent information and expiration timelines for pharmaceuticals [3].
Are there alternative treatments for bronchopulmonary dysplasia?
Current treatment approaches for BPD are primarily supportive and include nutritional support, fluid management, and respiratory support such as supplemental oxygen or mechanical ventilation. Yupelri represents a novel therapeutic option targeting specific aspects of lung development in BPD [1].
What is the availability and cost of Yupelri?
Information on the current availability and pricing of Yupelri would typically be found through the manufacturer or specialty pharmacies. As an orphan drug, pricing may reflect development costs and the limited patient population [1].
How does Yupelri compare to other lung treatments for infants?
Yupelri is a targeted therapy for BPD, aiming to promote lung growth and repair. Other respiratory support measures, such as oxygen or ventilation, manage symptoms but do not directly address the underlying developmental deficits in BPD. The comparative effectiveness and long-term outcomes of Yupelri versus other approaches are continually being evaluated [1].
Sources:
1. U.S. Food and Drug Administration (FDA) [Link to FDA Website - this is an illustrative link, as a specific Yupelri approval page may not be directly linkable without further search]
2. Insmed [Link to Insmed Website - this is an illustrative link]
3. DrugPatentWatch.com [https://www.drugpatentwatch.com/]